Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab. Two established xenograft models re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Oncol
Asıl Yazarlar: Borgan, Eldrid, Lindholm, Evita M., Moestue, Siver, Mælandsmo, Gunhild M., Lingjærde, Ole Christian, Gribbestad, Ingrid S., Børresen-Dale, Anne-Lise, Engebraaten, Olav, Sørlie, Therese
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2012
Konular:
Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528408/
https://ncbi.nlm.nih.gov/pubmed/23142657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller